Johnson & Johnson (NYSE:JNJ) is Employers Holdings Inc.’s 8th Largest Position

Employers Holdings Inc. trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 4.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,897 shares of the company’s stock after selling 1,020 shares during the period. Johnson & Johnson accounts for about 1.8% of Employers Holdings Inc.’s investment portfolio, making the stock its 8th biggest holding. Employers Holdings Inc.’s holdings in Johnson & Johnson were worth $3,220,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. First Fiduciary Investment Counsel Inc. lifted its position in Johnson & Johnson by 0.6% during the 2nd quarter. First Fiduciary Investment Counsel Inc. now owns 123,812 shares of the company’s stock valued at $17,412,000 after acquiring an additional 698 shares during the period. Nottingham Advisors Inc. lifted its position in Johnson & Johnson by 12.5% during the 2nd quarter. Nottingham Advisors Inc. now owns 4,507 shares of the company’s stock valued at $644,000 after acquiring an additional 500 shares during the period. Teza Capital Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at about $1,271,000. Krane Funds Advisors LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth approximately $367,000. Finally, Fragasso Group Inc. grew its stake in shares of Johnson & Johnson by 1.6% in the second quarter. Fragasso Group Inc. now owns 33,259 shares of the company’s stock worth $4,942,000 after acquiring an additional 535 shares during the period. 68.44% of the stock is owned by institutional investors.

In related news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the sale, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.27% of the stock is owned by corporate insiders.

JNJ has been the topic of several analyst reports. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Citigroup boosted their price target on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Credit Suisse Group restated a “buy” rating and issued a $161.00 price target on shares of Johnson & Johnson in a research report on Tuesday, April 28th. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus price target of $163.38.

NYSE JNJ opened at $152.06 on Wednesday. The company’s 50-day moving average price is $147.76 and its 200-day moving average price is $144.18. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.40. The stock has a market cap of $400.58 billion, a PE ratio of 22.23, a PEG ratio of 3.37 and a beta of 0.68. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company had revenue of $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. During the same period in the prior year, the firm earned $2.58 earnings per share. The firm’s revenue for the quarter was down 10.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Johnson & Johnson will post 7.85 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be paid a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a yield of 2.66%. The ex-dividend date of this dividend is Monday, August 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: What is the Beige Book?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.